PharmaVigilant
today announced the release of I-Accountability, a drug accountability system that efficiently tracks and controls drug inventory and randomization. As trials become larger and more complex, I-Accountability centralizes and automates the drug accountability process, decreasing workload at the sites, improving compliance and drastically advancing study timelines. I-Accountability provides PharmaVigilant with a competitive advantage with the QR code feature, providing clients with immediate access to inventory status through their smartphones.
I-Accountability is easier to use than manual, paper-based tracking. It provides a user-friendly means of randomization, supply management, and ongoing drug monitoring. In terms of patient randomization, I-Accountability replaces phone and paper based randomization methods and automatically retrieves randomization numbers and corresponding details. This process triggers email alerts to notify shippers and other participants of medication requirements throughout the supply chain, keeping the Sponsor aware of all activities.
Once randomization has occurred, I-Accountability automates the collection of the medication by using state of the art technology to generate QR Codes for each medical product. This allows a ‘Mobile’ interface to interact with the system, so that once the drug is received at the site, any smartphone QR Code App can scan the barcodes to automatically record the receipt and product condition.
Upon drug administration at the site, clinicians receive and enter information concerning dispensation and usage into the EDC system, creating an interoperable feedback cycle that drives the replenishment process. In the event of a damaged product, I-Accountability provides the creation of reorder requests, reducing the amount of time for site staff to conduct tasks.
“I-Accountability offers clients a complete life-cycle service for their clinical trial medications,” says James DeSanti, President and CEO, PharmaVigilant. “In seconds, Sponsors can view a summary of inventory tracking information in I-Accountability globally. With trials containing thousands of subjects across multiple sites/countries in need of study drugs or placebos, immediate access to this information is crucial in order to manage the drug/asset supply chain. We have incorporated QR code functionality to leverage mobile hardware already existent in the field. Smartphones are everywhere, so adding QR codes to medical products will streamline the shipping and receiving process, giving PharmaVigilant a competitive advantage.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.